ALLG MM13 Published in Journal of Clinical Oncology


In a significant advancement for patients living with systemic light-chain (AL) amyloidosis, the main publication for the ALLG MM13 clinical trial led by ALLG Scientific Advisory Committee Chair, Associate Professor Peter Mollee, has been published online in the Journal of Clinical Oncology.

This trial was an important international collaboration with the European Myeloma Network (EMN), bringing new therapies to Australian patients with AL amyloidosis, particularly new combinations of therapies.

The objective of ALLG MM13 was to compare responses to Melphalan and Dexamethasone (“MDex”) with those of Bortezomib, Melphalan and Dexamethasone (“BMDex”) in previously untreated patients with AL amyloidosis.

The results of the trial, as presented in the open-access publication, are unprecedented in AL amyloidosis. The trial showed that bortezomib significantly improved response rates and overall survival, with the absolute improvement in survival of approximately 30% with the addition of bortezomib a staggering result almost never seen in blood disorders.

Read more in the full August issue of ALLG News here.